StockData

RxSight, Inc. (RXST) stock

RXSTNasdaqOphthalmic GoodsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3074% below fair value
$5.30−0.02 (-0.38%)

Close on Nov 16, 2026Market cap $220.44MP/E –Yield –

RxSight price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

RxSight's price to sales ratio was 1.7× on Nov 11, 2026, against 3.3× a year earlier. Over the last 5 years it ranged from 1.6× to 22.1×, with a median of 10.3×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20261.7×−1.3
2025Dec 31, 20253.0×−7.8
2024Dec 31, 202410.8×−8.1
2023Dec 29, 202318.9×+10.4
2022Dec 30, 20228.5×−7.6
2021Dec 31, 202116.1×–

More RxSight figures

See a number that looks wrong?